COVID-19 Bivalent Booster Megastudy
NCT05607082 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2600000
Last updated 2023-03-03
Summary
This megastudy is a massive randomized controlled trial. By randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions to one another and to a control group (in which individuals will only receive the usual communications from their partner organization) to identify which interventions significantly increase vaccination rates. Pharmacy customers will be randomly assigned to receive one of the interventions designed by team scientists to encourage vaccination or to a control group. The baseline intervention will be based on the top-performing SMS intervention identified in the investigators previous megastudies on encouraging vaccination (Milkman et al., 2021b, 2022). Pharmacy customers will receive SMS messages conveying that a COVID booster vaccine is reserved or waiting for them at the pharmacy. Additional behavioral science messaging strategies will be tested by building off of this baseline intervention.
Conditions
Interventions
- BEHAVIORAL
-
COVID Booster text messages
Participants will receive text messages per descriptions listed in the arms.
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-11-03
- Primary Completion
- 2022-12-08
- Completion
- 2023-02-06
Countries
- United States
Study Locations
More Related Trials
-
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
NCT05405283 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
NCT05541861 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
NCT04652102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
NCT05925127 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
NCT04368728 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
NCT04889209 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
NCT06923137 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
NCT04614948 ·Status: COMPLETED ·Phase: PHASE3
-
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
NCT05279365 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
NCT04505722 ·Status: COMPLETED ·Phase: PHASE3
-
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
NCT05876377 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
NCT04713553 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
NCT05212610 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
NCT04999111 ·Status: COMPLETED ·Phase: PHASE2
-
The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine
NCT05273528 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19
NCT05079217 ·Status: UNKNOWN ·Phase: PHASE4
-
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
NCT04551898 ·Status: COMPLETED ·Phase: PHASE2
-
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
NCT05329220 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
NCT05373485 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
NCT06255626 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
NCT05373472 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults
NCT05907044 ·Status: COMPLETED ·Phase: NA
-
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
NCT05525208 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes
NCT05886790 ·Status: UNKNOWN ·Phase: NA